Analytical Data
-
Gene name
CTACK/CCL27
- Application
-
Alternative Names
CC chemokine ILC, CTACK, ESkine, IL-11 R-alpha-locus chemokine, Skinkine
-
Species
Human
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 96% as determined by SDS-PAGE.
-
Uniprot
Q9Y4X3
-
Expression Region
25-112aa
-
Protein Length
Partial
-
Molecular Weight
10.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CTACK (C-C Motif Chemokine Ligand 27), also known as CCL27, is a chemokine that plays a crucial role in immune cell recruitment, particularly in skin-associated responses and inflammation. It primarily attracts memory T cells to skin tissues, thereby contributing to various dermatological conditions and immune responses. Research on CCL27 has garnered significant interest due to its potential implications in skin diseases such as psoriasis, eczema, and allergic contact dermatitis. The recombinant expression of CCL27 allows for a detailed study of its biological functions and elucidation of underlying mechanisms in skin immunity. By utilizing advanced biotechnological approaches, scientists can produce this protein in a controlled environment, facilitating investigations into its structure-function relationships and interactions with receptors like CCR10. Understanding CCL27's role can aid in the development of novel therapeutic strategies targeting skin inflammation and enhancing immune responses in dermatological disorders. As such, the study of CTACK/CCL27 recombinant protein holds promise for both fundamental immunological research and potential clinical applications, paving the way for innovative treatments aimed at modulating skin immunity and improving patient outcomes in various skin-related diseases.
